Ginkgo Bioworks is a biotechnology company dedicated to the development and application of biomanufacturing. Founded in 2008, it is headquartered in Boston, Massachusetts and has nearly 1300 full-time employees.
Ginkgo Bioworks operates in the healthcare and biotechnology sectors and produces a platform for cell programming that is used to program cells and enable the development of products like novel therapeutics, food ingredients, and chemicals derived from petroleum. These products are used in specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
Ginkgo Bioworks provides a comprehensive range of services, from product design and product engineering to analytical chemistry, regulatory affairs, and process optimization. The company is particularly known for its pioneering work in the development of synthetic biology, a field that allows us to engineer living systems for a range of applications.
The company’s mission is to accelerate biotechnology, creating new and infinite products from the natural world and revolutionizing industries, while using responsible and sustainable practices.
Ginkgo Bioworks is an American biotechnology company that designs, engineers, and manufactures biological organisms. The company has made a successful transition from offering value-added products and services to pursuing a broader approach to biological engineering.
Performance-wise, the company is highly successful. Ginkgo Bioworks has a quick ratio of 6.73, gross margins of 63.81%, and a return on assets of -48.79%. This indicates that it has strong liquidity, is highly profitable and has achieved an impressive ROA figure that reflects profitability.
The number of analysts who have released opinions on the company currently stands at 8. The current share price of Ginkgo Bioworks stands at 1.59, with the target mean price reaching 4.24. In terms of profit margins, it stands at 0.00%, indicating that the company is mostly in the business of gaining revenues through other sources.
Total cash per share stands at 0.58, revenue per share at 0.22, and gross profits at 273.49M. The revenue growth recorded by the company stands at -52.10%, and the total debt stands at 404.1M. The operating margins for the company stand at -447.90%, with a debt-to-equity ratio of 25.14.
On the recommendation front, the current mean recommendation of Ginkgo Bioworks stands at buy, with the target low and high prices standing at 1.25 and 12.00, respectively. The return on equity currently stands at -106.70%, and the operating cash flow at -322.88M.
Overall, Ginkgo Bioworks is performing well in all the categories mentioned above, indicating that the company is a strong contender in the field of biotechnology.
Ginkgo Bioworks does not shy away from the effects of an economic recession. In the event of a recession, Ginkgo Bioworks takes a proactive approach to ensure its performance is maximized and its revenue buffer is not affected.
The company has a comprehensive strategy for recessionary times. First, Ginkgo Bioworks focuses on cost containment and reducing operating expenses. Spending on personnel is optimized and discretionary expenditures are minimized. Second, the company takes a proactive approach to new customer acquisition and investing its resources into developing and strengthening existing customer relationships. Third, Ginkgo Bioworks protects its revenue buffer, aiming to minimize the impact of decreased client demand. Finally, the company takes a conservative approach to balance sheet management and liquidity, managing financial risks to ensure that it is not exposed to significant liquidity risk.
These strategies have been key in helping Ginkgo Bioworks navigate recessionary times. By being proactive and focusing on cost containment and customer acquisition, the company has been able to optimize its performance and protect its revenue, ensuring continued success in times of recession. By harnessing its expertise in synthetic biology and the principles of biomanufacturing, Ginkgo Bioworks is positioned to not only withstand recessions but thrive during them.
When faced with high inflation or currency devaluation, Ginkgo Bioworks takes a number of steps to protect itself and its customers from the rising costs of production and materials. Firstly, Ginkgo Bioworks monitors economic developments carefully and makes use of hedging strategies to mitigate currency risk. These strategies involve the use of contracts or derivatives that enable them to secure a fixed price of input supplies irrespective of the fluctuations in the currency markets. Secondly, Ginkgo Bioworks has diversified its supplier base to reduce exposure to the effects of currency markets.
Thirdly, the company works very closely with its customers to ensure that they are fully aware of their needs and requirements such that the company is able to produce and deliver their products and services in a cost effective way. Finally, the company establishes long term partnerships with its customers to ensure that they deliver high quality products and services in the most cost-effective manner.
In short, Ginkgo Bioworks is well-prepared and can continue to operate even in the face of high inflation or currency devaluation, providing its customers with quality products and services and creating value for both the company and its customers.
The risks associated with the stock include the uncertainty of biotech companies in general, the volatile nature of the biotechnology industry, uncertain regulatory approval, reliance on R&D and third party collaborations, intellectual property infringement, and cybersecurity threats. Additionally, market demand and pricing, foreign currency exchange, and competitive pressures are other risks that could impact the stock of Ginkgo Bioworks.
